Piper Sandler initiated coverage of Nuvalent (NUVL) with an Overweight rating and $112 price target The shares are underestimating the company’s near-term value creation over the next 18 months, the analyst tells investors in a research note. The firm believes Nuvalent’s updated Phase II neladalkib data later this year which will confirm differentiation versus lorlatinib.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent Reports Q2 2025 Financials and Pipeline Progress
- Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
- Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating
- Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
- Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating